Celebrated at the recent 2014 Congress of the European Society for Medical Oncology (ESMO), 26 – 28 September (Madrid, Spain),…
news
The FC Barcelona Foundation and the Vall d’Hebron Institute of Oncology have signed a collaborative agreement to raise awareness about…
Recent VHIO study reveals that tumor cell sensitivity and resistance to therapy with cetuximab in colorectal cancer can be detected…
Arkaitz Carracedo, Group Leader of the Cell Signalling and Metabolism in Cancer Group at CIC bioGUNE in the Basque Country…
El Instituto de Oncología de Vall d’Hebron (VHIO) junto con el Hospital Universitario Vall d’Hebron (HUVH) han unido fuerzas para…
Barcelona, 16 October 2014. The Vall d´Hebron Institute of Oncology (VHIO) and the Vall d´Hebron University Hospital (HUVH) have joined…
➢ The combination of chemotherapy and selective therapy with trastuzumab has for the very first time been shown as an…
High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery; PD-L1 protein a possible immunotherapy target Is PD-L1 a…
Long-term follow-up from CLEOPATRA study presented at ESMO 2014 demonstrates ‘unprecedented’ benefit Lugano/Madrid, 28 September 2014 — Patients with HER2-positive…
